Leqembi IQLIK injection training teaches caregivers to give a once-weekly subcutaneous dose of lecanemab-irmb for early Alzheimer's at home. Training covers device use and handling, while brain safety monitoring and dose clearance remain with the prescriber. Leqembi IQLIK is an autoinjector form of Leqembi, a drug that targets amyloid-beta in the brain. According to Eisai and Biogen, the FDA approved it on July 13, 2026 as a starting treatment at 500 mg weekly, given as two 250-mg injections of about 15 seconds each the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What injection training covers
- What home treatment changes
- Who treatment fits and what safety checks remain
- Questions to ask the prescriber
What injection training covers
Training focuses on device skills, not medical decisions. Eisai reports that Nurse Educators teach injection steps in person or virtually through a device-only education program. Caregivers practice preparation, injection angle and hold time, site rotation, and disposal.
The LEQEMBI Companion program adds tracking tools and support resources, according to Eisai. Training ends with a practical check. The FDA label requires a healthcare professional to directly supervise at least two consecutive doses and confirm home use is appropriate, with regular reassessment thereafter the prescribing information summary.
What home treatment changes
Home injections remove routine infusion-center visits after training and prescriber clearance, according to Eisai and Biogen reporting via BioSpace the approval report. Families gain a fixed weekly routine instead of travel and infusion time. That convenience adds responsibility.
The caregiver must store autoinjectors as directed, track dose days, watch for missed doses, and keep follow-up visits. A home start also means early planning matters. Families need backup injectors for vacations, a second trained helper for sick days, and a clear contact plan for side effects.
Who treatment fits and what safety checks remain
Treatment is limited to early disease. The Alzheimer's Association states it is for mild cognitive impairment or mild dementia due to Alzheimer's, with amyloid-beta confirmed by PET or spinal-fluid testing the Association treatment page. Safety monitoring continues after training.
Leqembi labeling carries a boxed warning for amyloid-related imaging abnormalities, or ARIA, meaning brain swelling or small bleeds that are often silent but can be serious or fatal. Safe prescribing requires a recent baseline brain MRI, scheduled follow-up MRIs, and ApoE epsilon-4 testing to inform ARIA risk, especially for homozygotes and anticoagulant users. Caregivers do not order or interpret these tests, but they must get the patient to them.
Questions to ask the prescriber
Bring a short list to the clearance visit. Clear answers prevent delays and unsafe home starts.
- Are we confirmed eligible by diagnosis, amyloid test, MRI, and ApoE result?
- Who will supervise our first two injections, and what must we demonstrate?
- How often will you reassess our technique and review MRI results?
- What symptoms should prompt an urgent call, and which clinic number do we use day and night?
- What is the plan if we miss a weekly dose, travel, or develop illness or bleeding risk?
